BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33714638)

  • 1. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
    Helbig G; Klion AD
    Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic myeloid neoplasms.
    Noel P; Mesa RA
    Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
    Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
    Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
    Kjeldsen E
    Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern diagnosis and treatment of primary eosinophilia.
    Tefferi A
    Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypereosinophilic syndrome and proliferative diseases.
    Ionescu MA; Wang L; Janin A
    Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
    Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophilia in Hematologic Disorders.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
    Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.